HemoGenix Will Use HALO Tech to Evaluate ImmuneRegen BioSciences Rx Candidate | GenomeWeb
Contract research-service lab HemoGenix this week said it will use its internally developed and validated in vitro assays to help development-stage biotech shop ImmuneRegen BioSciences test its therapeutic candidate Homspera.
 
A derivative of substance P, a peptide immunomodulator and homeostatic compound that improves pulmonary function and stimulates the immune system, Homspera is designed to be used as a countermeasure against bioterrorist threats, the manufacturer said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.